First-line management of CML: A state of the art review

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue SUPPL. 2, 2008, Pages

  Hochhaus, Andreas ^a,b  

^a University of Heidelberg ^*

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allo SCT; CML; Imatinib; Interferon alfa

Indexed keywords

ALPHA INTERFERON; CYTARABINE; DASATINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; NILOTINIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

ALLOGENEIC STEM CELL TRANSPLANTATION; BIRTH DEFECT; CANCER GROWTH; CANCER RELAPSE; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; HEART DISEASE; HUMAN; LUNG EDEMA; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATIENT CARE; PATIENT MONITORING; PREGNANCY; REVIEW; SPONTANEOUS ABORTION; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TRANSPLANTATION, HOMOLOGOUS;

EID: 45749083360     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-293.
2. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-667.
3. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993;82:398-407.
4. Hashimoto T, Ohtaki M, Ueoka H, et al. Estimation of chronic phase duration in Ph-positive chronic myelocytic leukemia treated with busulfan: statistical analysis on Japanese patients. Int J Hematol 1994;60:59-69.
5. Hochhaus A, Lin F, Reiter A, et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol 1995;91: 126-131.
6. Hehlmann R. Current CML therapy: progress and dilemma. Leukemia 2003;17:1010-1012.
7. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074-3081.
8. Cortes J, Kantarjian H, O'Brien S, et al. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996;100:452-455.
9. Mauro MJ, Maziarz RT. Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used? Mayo Clin Proc 2006;81:404-416.
10. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17(Suppl 3):S5-6.
11. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-968.
12. Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007;109:4686-4692.
13. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087-1092.
14. Kebriaei P, Detry MA, Giralt S, et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning for patients with chronic myeloid leukemia. Blood 2007;110:3456-3462.
15. Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969-2976.
16. Giralt SA, Arora M, Goldman JM, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007;137:461-467.
17. Apperley JF. Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program 2006:226-232.
18. Kaeda J, O'Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006;107: 4171-4176.
19. van Rhee F, Savage D, Blackwell J, et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998;21: 1055-1061.
20. Dazzi F, Fozza C. Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. Best Pract Res Clin Haematol 2007;20:311-327.
21. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23-380-394.
22. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
23. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003;17:2401-2409.
24. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
25. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478-1484.
26. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820.
27. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349: 1423-1432.
28. O'Brien S, Berman E, Devetten MP, et al. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, Version 2.2008. Available at: http://www.nccn.org/physician_gls/index.html. Accessed November 11, 2007.
29. Iacobucci I, Saglio G, Rosti G, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006;12:3037-3042.
30. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916.
31. Kantarjian HM, Larson RA, Guilhot F, et al. Declining rates of adverse events (AEs), rare occurrence of serious AEs (SAEs), and no unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) initially treated with imatinib (IM) in the International Randomized Study of Interferon vs STI571 (IRIS) [abstract]. Blood 2006;108:605a; Abstract 2136.
32. Atallah E, Durand JB, Kantarjian H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110: 1233-1237.
33. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103: 2873-2878.
34. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-3432.
35. Bao F, Munker R, Lowery C, et al. Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias. Mol Diagn Ther 2007;11:239-245.
36. Winn-Deen ES, Helton B, Van Atta R, et al. Development of an integrated assay for detection of BCR-ABL RNA. Clin Chem 2007;53:1593-1600.
37. Martinelli G, Iacobucci I, Soverini S, et al. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. Hematol Oncol 2006;24:196-204.
38. Martinelli G, Iacobucci I, Rosti G, et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Ann Oncol 2006;17:495-502.
39. Wang L, Knight K, Lucas C, et al. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006;91:235-239.
40. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007;370:342-350.
41. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program 2005:183-187.
42. Corbin AS, La Rosee P, Stoffregen EP, et al. Several BCR-ABL kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101:4611-4614.
43. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-2196.
44. Müller MC, Erben P, Schenk T, et al. Response to dasatinib after imatinib failure according to type of preexisting BCR-ABL mutations [abstract]. Blood 2006;108:225a; Abstract 748.
45. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant ABL kinase domain mutants. Cancer Res 2005;65:4500-4505.
46. Jabbour E, Cortes J, O'Brien S, et al. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol 2007;44(Suppl 1):S25-31.
47. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.
48. Verbeek W, Konig H, Boehm J, et al. Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia. Acta Haematol 2006;115:109-112.
49. Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002;20: 214-220.
50. Merante S, Orlandi E, Bernasconi P, et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005;90:979-981.
51. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
52. Ghanima W, Kahrs J, Dahl TG III, et al. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur J Haematol 2004;72:441-443.
53. Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005;23:7583-7593.
54. Breccia M, Diverio D, Pane F, et al. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leuk Res 2006;30:1577-1579.
55. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104:2204-2205.
56. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-2309.
57. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-3546.
58. Ali R, Ozkalemkas F, Ozcelik T, et al. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 2005;29:971-973.
59. Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006;24:1204-1208.
60. Garderet L, Santacruz R, Barbu V, et al. Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica 2007;92(3 Suppl):ECR05.
61. Ramasamy K, Hayden J, Lim ZiYi, et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 2007;137:374-383.
62. Dowding C, Gordon M, Guo AP, et al. Potential mechanisms of action of interferon-alpha in CML. Leuk Lymphoma 1993;11(Suppl 1):185-191.
63. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-325.
64. Hochhaus A, Fischer T, Brummendorf T, et al. Imatinib (Glivec) and PEG-interferon α2a (Pegasys) phase I/II combination study in chronic phase chronic myeloid leukemia (CML) [abstract]. Blood 2002;100: 163a; Abstract 612.
65. Baccarani M, Martinelli G, Rosti G, et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 2004;104:4245-4251.
66. Branford S, Hughes T, Stylian S, et al. Significant reduction of BCR-ABL transcripts after switching to imatinib therapy in patients with CML and complete or near-complete cytogenetic responses to interferon-alpha (IFN) [abstract]. Blood 2006;108:607a; Abstract 2142.
67. Quintas-Cardama A, Kantarjian HM, Ravandi F, et al. Immune modulation of minimal residual disease (MRD) in patients (pts) with chronic myelogenous leukemia (CML) in early chronic phase (CP): a randomized trial of frontline high-dose (HS) imatinib mesylate (IM) with of without pegylated-ninterferon (PEG-IFN) and GM-CSF [abstract]. Blood 2006;108:626a; Abstract 2207.
68. Quintas-Cardama A, Kantarjian HM, Giles F, et al. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost 2006;32(4 Pt 2):409-416.
69. Guerci A, Nicolini F, Maloisel F, et al. Randomized comparison of imatinib with imatinib combination therapies in newly diagnosed chronic myelogenous leukemia patients in chronic phase: design and first interim analysis of a phase III trial from the French CML Group [abstract]. Blood 2005;106:53a; Abstract 168.
70. Cortes J, Talpaz M, O'Brien S, et al. A randomized trial of high-dose (HD) imatinib mesylate (IM) with or without peg-interferon (PEC-IFN) and GM-CSF as frontline therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP) [abstract]. Blood 2005;106:316a; Abstract 1084.
71. Berger U, Hochhaus A, Reiter A, et al. Feasibility of imatinib combination therapies in a randomized trial for chronic myeloid leukemia: the German CML-Study IV - pilot phase [abstract]. Blood 2004;104:11a; Abstract 24.
72. Cortes J, O'Brien S, Jones D, et al. Dasatinib (SPRYCEL) in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP) [abstract]. Blood 2006;108: 613a; Abstract 2161.
73. Jabbour E, Cortes J, Giles F, et al. Preliminary activity of nilotinib (AMN107), a novel selective potent oral BCR-ABL tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP) [abstract]. Blood 2006;108:616a; Abstract 2172.